CVrg KOL Insights: answers to crucial questions
CVrg KOL Insights reports are the result of qualitative primary research conducted annually by our analysts to deeply explore key non-proprietary questions focusing on the most important issues facing product development and management. Though CVrg experts routinely interact with Key Opinion Leaders throughout the year, in select disease areas, more consolidated KOL research is essential to encompass KOL thoughts in areas of high interest and research activity. Through in-depth interviews with carefully selected KOLs, we harness multiple perspectives and evaluate emerging research and treatment trends with resulting implications for the field.
Our researchers begin by forming investigative questions based on the most important issues they see facing new therapies in development. These questions create comprehensive discussion guides which are then forwarded to subscribers for input, aligning our primary research to answer pressing questions our clients face today.
With the discussion guides in hand, CVrg analysts interview KOLs by phone in the US, EU, and in select disease areas in Japan. KOL opinions and perspectives are documented that include their thoughts about future changes to treatment guidelines, current treatment trends and unmet needs, promising areas of preclinical research, target product profiles, and profiles for use with new therapies in development.
These primary research findings are compiled into CVrg KOL Insights reports, encapsulating areas of KOL consensus and debate, and analyzing implications for new treatment development. Subscribing clients may schedule a debrief of our findings, including a private Q&A with our experts for no additional cost.
Current areas of KOL research report coverage in CVM include Dyslip/Athero, HF, CKD, and T2D.
CVrg KOL Insight reports harness multiple KOL perspectives and evaluate emerging research and treatment trends with resulting implications for cardiovascular and metabolic disease markets.
“I thank you and your team for the excellent work you do, greatly facilitating our decision making process.”
Chief of Staff to the President, Global R&D